Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Reproduction ; 161(1): 11-19, 2021 01.
Artículo en Inglés | MEDLINE | ID: mdl-33112285

RESUMEN

Endometriosis is a common gynecological disease in reproductive-age women. Although the hormone-dependent therapy is the first line treatment for endometriosis, it is not a curative regimen and associated with severe side-effects, which significantly decrease the life quality of affected individuals. To seek a target for treatment of endometriosis, we focused on plasma membrane proteins that are elevated in ectopic cells and exert beneficial effects in cell growth and survival. We performed bioinformatics analysis and identified the neurotrophic receptor tyrosine kinase 2 (NTRK2) as a potential candidate for treatment. The expression levels of NTRK2 were markedly upregulated in the lesions of clinical specimen as well as in the mouse endometriotic-like lesion. Mechanistic investigation demonstrated that upregulation of NTRK2 is induced by hypoxia in a hypoxia-inducible factor 1 alpha-dependent manner. Knockdown of NTRK2 or administration of ANA-12, a selective antagonist of NTRK2, significantly induced endometriotic stromal cells death, suggesting it may be a potential therapeutic agent. In vivo study using surgery-induced endometriosis mice model showed ANA-12 (1.5 mg/kg body weight) treatment induced apoptosis of endometriotic cells and caused the regression of ectopic lesions. Taken together, our findings suggest a possible mechanism responsible for the aberrant expression of NTRK2 in endometriotic lesions and this may be involved in the pathogenesis of endometriosis.


Asunto(s)
Endometriosis/tratamiento farmacológico , Glicoproteínas de Membrana/metabolismo , ARN Interferente Pequeño/uso terapéutico , Receptor trkB/metabolismo , Animales , Coristoma/metabolismo , Evaluación Preclínica de Medicamentos , Endometriosis/metabolismo , Femenino , Humanos , Glicoproteínas de Membrana/antagonistas & inhibidores , Ratones Endogámicos C57BL , Terapia Molecular Dirigida , Cultivo Primario de Células , ARN Interferente Pequeño/farmacología , Receptor trkB/antagonistas & inhibidores , Células del Estroma/metabolismo
2.
J Pathol ; 242(4): 476-487, 2017 08.
Artículo en Inglés | MEDLINE | ID: mdl-28608501

RESUMEN

Endometriosis is a highly prevalent gynaecological disease that severely reduces women's health and quality of life. Ectopic endometriotic lesions have evolved mechanisms to survive in the hypoxic peritoneal microenvironment by regulating the expression of a significant subset of genes. However, the master regulator controlling these genes remains to be characterized. Herein, by using bioinformatics analysis and experimental verification, we identified yes-associated protein 1 (YAP1) as a master regulator of endometriosis. Nuclear localization and transcriptional activity of YAP1 were up-regulated by hypoxia via down-regulation of LATS1, a kinase that inactivates YAP1. Disruption of hypoxia-induced YAP1 signalling by siRNA knockdown or inhibitor treatment abolished critical biological processes involved in endometriosis development such as steroidogenesis, angiogenesis, inflammation, migration, innervation, and cell proliferation. Treatment with a YAP1 inhibitor caused the regression of endometriotic lesions without affecting maternal fertility or the growth rate of offspring in the mouse model of endometriosis. Taken together, we identify hypoxia/LATS1/YAP1 as a novel pathway for the pathogenesis of endometriosis and demonstrate that targeting YAP1 might be an alternative approach to treat endometriosis. Copyright © 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.


Asunto(s)
Proteínas Adaptadoras Transductoras de Señales/antagonistas & inhibidores , Endometriosis/tratamiento farmacológico , Fertilidad/efectos de los fármacos , Fosfoproteínas/antagonistas & inhibidores , Proteínas Adaptadoras Transductoras de Señales/biosíntesis , Proteínas Adaptadoras Transductoras de Señales/genética , Proteínas Adaptadoras Transductoras de Señales/fisiología , Animales , Proteínas de Ciclo Celular , Hipoxia de la Célula/genética , Hipoxia de la Célula/fisiología , Biología Computacional/métodos , Modelos Animales de Enfermedad , Evaluación Preclínica de Medicamentos/métodos , Endometriosis/etiología , Endometriosis/genética , Endometriosis/metabolismo , Femenino , Regulación de la Expresión Génica/fisiología , Técnicas de Silenciamiento del Gen , Estudio de Asociación del Genoma Completo , Humanos , Ratones Endogámicos C57BL , Terapia Molecular Dirigida/métodos , Fosfoproteínas/biosíntesis , Fosfoproteínas/genética , Fosfoproteínas/fisiología , Porfirinas/farmacología , Porfirinas/uso terapéutico , Proteínas Serina-Treonina Quinasas/biosíntesis , Proteínas Serina-Treonina Quinasas/genética , ARN Mensajero/genética , ARN Interferente Pequeño/genética , Células del Estroma/metabolismo , Factores de Transcripción , Transcripción Genética , Verteporfina , Proteínas Señalizadoras YAP
3.
Exp Dermatol ; 19(5): 470-2, 2010 May.
Artículo en Inglés | MEDLINE | ID: mdl-20337700

RESUMEN

Human sebaceous gland possesses all the steroidogenic enzymes required for androgen synthesis. It remains unclear whether the testosterone produced in situ mainly derives from circulating dehydroepiandrosterone (DHEA) or from de novo synthesis utilizing serum cholesterol. Using testosterone radioimmunoassay, we found that testosterone was barely detectable in the supernatant of cultured human SZ95 sebocytes when cholesterol was added alone, indicating a low basal expression of steroidogenic acute regulatory protein (StAR) in SZ95 cells. Human chorionic gonadotropin and fibroblast growth factor-9 were as potent as forskolin in activating StAR to enhance testosterone production, while interleukin-1 beta, dexamethasone, insulin and insulin-like growth factor-1 showed no stimulatory effect. A two-fold increase of testosterone production was observed in supplementation of DHEA as compared to pregnenolone, progesterone or 17 alpha-hydroxyprogesterone. Based on our findings, testosterone synthesized in cultured sebocytes derived mainly from DHEA and inhibition of 3beta-hydroxysteroid dehydrogenase and 17beta-hydroxysteroid dehydrogenase may be a new target of androgen suppression for acne treatment.


Asunto(s)
Deshidroepiandrosterona/metabolismo , Glándulas Sebáceas/citología , Testosterona/biosíntesis , 17-alfa-Hidroxiprogesterona/metabolismo , Línea Celular Transformada , Colesterol/metabolismo , Gonadotropina Coriónica/farmacología , Colforsina/farmacología , CMP Cíclico/análogos & derivados , CMP Cíclico/farmacología , Dexametasona/farmacología , Femenino , Factor 9 de Crecimiento de Fibroblastos/farmacología , Humanos , Hidroxicolesteroles/metabolismo , Insulina/farmacología , Factor I del Crecimiento Similar a la Insulina/farmacología , Interleucina-1beta/farmacología , Pregnenolona/metabolismo , Progesterona/metabolismo , Glándulas Sebáceas/metabolismo
4.
Biol Reprod ; 70(5): 1358-64, 2004 May.
Artículo en Inglés | MEDLINE | ID: mdl-14711788

RESUMEN

There is increasing evidence that 17beta-estradiol (E2) directly influences the quality of maturing oocytes and thus the outcome of assisted reproduction treatment. Although Cordyceps sinensis (CS) mycelium, a Chinese herbal medicine, is believed to enhance libido and fertility in both sexes, the mechanism of its effect in women has not been determined. The aim of the present study was to evaluate the effects of CS on steroidogenic enzyme expression and E2 biosynthesis in human granulosa-lutein cells (GLC). We found that CS induced E2 production by GLC in a dose- and time-dependent manner and that a 3-h treatment with CS induced increased levels of mRNAs coding for the P450 side chain cleavage enzyme (P450scc), 3beta-hydroxysteroid dehydrogenase (3beta-HSD), and aromatase. Western blot analysis demonstrated that, after treatment with CS for 3 h, protein levels of steroidogenic acute regulatory protein (StAR) and aromatase were upregulated while P450scc and 3beta-HSD levels showed no substantial change. New protein synthesis was required for CS-induced E2 production because it was abrogated by cycloheximide pretreatment. Addition of 22(R)-hydroxycholesterol, thus bypassing the need for StAR protein, did not induce as much E2 production as CS treatment, indicating that upregulation of StAR protein was not the only factor contributing to CS-induced steroidogenesis. Cotreatment of GLCs with CS and aminoglutethimide, an aromatase inhibitor, completely abolished CS-induced E2 production. In conclusion, treatment of GLCs with CS results in increased E2 production due, at least in part, to increased StAR and aromatase expression. These data may help in the development of treatment regimens to improve the success rate of in vitro fertilization.


Asunto(s)
Aromatasa/biosíntesis , Cordyceps , Estradiol/metabolismo , Células Lúteas/metabolismo , Micelio/fisiología , Ovario/metabolismo , Aromatasa/genética , Células Cultivadas , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Células Lúteas/enzimología , Fosfoproteínas/biosíntesis , ARN Mensajero/metabolismo , Factores de Tiempo , Regulación hacia Arriba
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA